Costco stock slips after-hours even as Bernstein lifts target — what to watch next
10 February 2026
1 min read

Costco stock slips after-hours even as Bernstein lifts target — what to watch next

New York, February 9, 2026, 19:26 EST — Trading after the bell.

  • Costco shares slipped in after-hours action, following a tepid finish in the main session
  • Bernstein raised its price target on Costco but stuck with the Outperform rating.
  • Costco’s quarterly numbers for March 5 and a fresh look at February sales are now in focus.

Costco Wholesale Corp slipped in after-hours action Monday, trading around $996.51, down about 0.1%. The stock had already notched a slight decline in the regular session, ending at $997.59.

Bernstein’s Zhihan Ma bumped up the price target on Costco to $1,155 from $1,146, sticking with an Outperform call. Ma pointed out that U.S. retail is “at an interesting juncture,” highlighting shaky consumer sentiment and a more complicated macro setup heading into fiscal 2026. TipRanks

Right now, calls like this carry real weight: Costco’s shares are tied directly to the narrative around consistent consumer spending—and the price tag investors are willing to put on dependable growth. High-multiple retailers like this can swing sharply when rates or inflation expectations shift, regardless of whether there’s any new company news.

Costco’s next key event lands March 5, when it reports fiscal second-quarter earnings alongside February sales figures. Wall Street will be watching comps—sales growth at stores open at least a year—and any clues about membership renewals, the profit engine here.

Outside of company news, traders are staring down a loaded week: big corporate earnings are coming up, along with crucial U.S. data on inflation and jobs—numbers that could quickly shift Fed policy forecasts. Those shifting rate forecasts? They tend to ripple right into defensive names such as Costco.

Bernstein flagged a tangled web of cross-currents—food inflation, policy risks, the works—that muddle any forecasts. At Costco, these factors surface in everything from foot traffic to demand for big-ticket items, and in just how hard the retailer pushes on pricing to keep members coming back.

After-hours action tends to be volatile. The stock edged lower late Monday, but stayed within its earlier band—no decisive shift there. Even so, it showed just how abruptly the market can shrug off a bullish call when traders are sitting tight for fresh numbers.

Bulls face one clear hazard: premium valuations don’t leave much room for slip-ups. Should shoppers ease spending, or if expenses eat in more than forecast, a “steady” retailer might still come up short.

Costco’s upcoming report has investors tuning in for management’s read on renewal rates, plus any signals on wage and freight costs. There’s also curiosity—will the company suggest anything more for shareholders on top of its standard dividend?

Next up: March 5. That’s when Costco is set to release its quarterly results, plus a look at February sales.

Stock Market Today

  • Q1 Earnings Review: FB Financial Vs Regional Banks
    May 14, 2026, 3:34 PM EDT. Regional banks, including FB Financial (NYSE:FBK), reported a mixed Q1 performance amid rising interest rates and economic uncertainties. FB Financial posted revenues of $172.7 million, up 30.8% year over year but missed analysts' revenue expectations by 1.7%, leading to a 5.7% stock decline post-report. Regionally focused banks saw average share price drops of 1.9% amid challenges like fintech competition, deposit withdrawals, and commercial real estate concerns. FB Financial's CEO, Christopher Holmes, highlighted the bank's customer trust recognition by J.D. Power and strong loan and deposit growth later in the quarter. This contrasts with stronger performers like UMB Financial, which outpaced peers in the quarter.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

14 May 2026
Smart Powerr shares jumped to 78.83 cents, up nearly 59 cents from the previous close, after hitting 90.37 cents intraday. The surge followed news that Nasdaq warned the company over its sub-$1 share price and possible suspension. Trading volume reached about 395 million shares. The company said a hearing request would delay any suspension but gave no assurance of keeping its Nasdaq listing.
Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal
Previous Story

Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal

RELX share price edges higher — what to watch before Thursday’s results
Next Story

RELX share price edges higher — what to watch before Thursday’s results

Go toTop